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Guanine nucleotide exchange factors (GEFs) directly
engage small GTPases to facilitate the exchange of
bound GDP for GTP, leading to GTPase activation. Sev-
eral recent crystal structures of GEFs in complex with
Rho family GTPases highlight the conserved interac-
tions and conformational alterations necessary for cat-
alyzing exchange. In the present study, functional roles
were defined for specific residues within Cdc42 impli-
cated by the crystal structures as important for physio-
logical exchange of guanine nucleotides within Rho
GTPases. In particular, this study highlights the para-
mount importance of the phosphate-binding loop and
interactions with the magnesium co-factor as critical for
proper regulation of RhoGEF-catalyzed exchange.
Other conformational alterations of the GTPases affect-
ing interactions with the sugar and base of guanine
nucleotides are also important but are secondary. Of
particular note, substitution of alanine for cysteine at
position 18 of Cdc42 leads to a fast cycling phenotype for
Cdc42 with heightened affinity for RhoGEFs and pro-
duces a dominant negative form of Cdc42 capable of
inhibiting RhoGEFs both in vitro and in vivo.
Similar to other members of the Ras superfamily, Rho family
GTPases are biologically active when bound to GTP and are
deactivated upon hydrolysis of GTP to GDP, a reaction typi-
cally accelerated by Rho GTPase-activating proteins (GAPs).1
Guanine nucleotide exchange factors (GEFs) rapidly convert
GTPases to their biologically active states by catalyzing the
exchange of GDP for GTP. Currently, Dbl (diffuse B-cell lym-
phoma) family members constitute the largest group of GEFs
for Rho GTPases (1–3) and are easily recognized by the invari-
ant placement of a pleckstrin homology (PH) domain immedi-
ately carboxyl-terminal to a Dbl homology (DH) domain. Iso-
lated DH domains typically possess significant exchange
potential that can be enhanced by the adjacent PH domain (4,
5). The invariant linkage of DH and PH domains hints at a
conserved function that is currently poorly understood.
As proposed for other GEFs, the reaction scheme for Dbl-
stimulated exchange includes the formation of a low affinity
GEFGTPaseGDPMg2 quaternary complex that rapidly con-
verts to a high affinity GEFGTPase binary complex concomi-
tant with expulsion of GDP and Mg2 (6). The reaction pro-
ceeds with the binding of GTPMg2 to form an unstable
quaternary complex of GEFGTPaseGTPMg2, followed by
dissociation of the GEF from the GTP-bound GTPase.
We have recently determined crystal structures of several
unique DH/PH fragments in complex with their cognate Rho
family GTPases (5, 7, 8), and the structures indicate a con-
served mechanism of exchange. For example, Rho GTPases
possess two “switch” regions that are conformationally sensi-
tive to the state of bound nucleotide, and these switch regions
occupy similar conformations in all current structures of Rho
GTPases bound to GEFs. Certain conformational features of
DH domain-bound Rho GTPases are also present in other
GEFGTPase structures, such as Sos1 (Cdc25 domain)Ras (9),
RCC1Ran (10), and SopECdc42 (11), and are indicative of
conserved aspects of the catalyzed exchange mechanism uti-
lized by various GEF families.
In order to more thoroughly understand the relative contri-
butions of key structural features in facilitating guanine nu-
cleotide exchange by RhoGEFs, Cdc42 and the Dbl family mem-
ber Dbs (for Dbl’s big sister) were mutated at critical sites, and
the functional consequences were determined. This analysis
indicates that mutations that affect Mg2 binding are critical
for efficient GEF-catalyzed exchange. Specifically, the methyl
group of Ala59 within Cdc42 or its equivalent in Rac1 and RhoA
normally impinges upon the Mg2 binding site within the
GEFGTPase complexes. Consequently, substitution of alanine
59 to glycine in Cdc42 severely cripples GEF binding and
exchange. Similarly, interactions that support the steric over-
lap of Ala59 and the Mg2-binding site also appear critical for
nucleotide exchange. Mutations that affect interactions with
the sugar or base of guanine nucleotides also have significant
effects on exchange, but these effects are secondary to disrup-
tion of Mg2 binding. One mutation (C18A) in Cdc42, designed
to disrupt a hydrogen bond with the -phosphate of guanine
nucleotides, is particularly notable, since it confers a dominant
negative phenotype upon Cdc42. Cdc42(C18A) is impaired in
nucleotide binding and consequently binds Dbs with higher
affinity than wild-type Cdc42. In vivo, Cdc42(C18A) exhibits a
dominant-negative phenotype, presumably by sequestering ex-
change factors in nucleotide-depleted complexes analogous to
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other, better characterized variants of Rho GTPases (i.e.
Cdc42(T17N)).
EXPERIMENTAL PROCEDURES
Guanine Nucleotide Exchange Assays—A carboxyl-terminal His6-
tagged, wild type DH/PH fragment (residues 623–967) expression con-
struct was derived from a cDNA library of mouse brain as described
previously (5). Mutations were introduced into wild type Dbs DH/PH
domain and Cdc42 using the QuikChange site-directed mutagenesis kit
(Stratagene) as per the manufacturer’s instructions. cDNA sequences of
all protein expression constructs were verified by automated sequencing.
Dbs and Cdc42 proteins were expressed and purified as described (5).
Fluorescence spectroscopic analysis of N-methylanthraniloyl (mant)-
GTP incorporation into bacterially purified Cdc42 and RhoA was car-
ried out using a PerkinElmer Life Sciences LS 50B spectrometer at
25 °C. Exchange assays containing 20 mM Tris, pH 7.5, 150 mM NaCl, 5
mM MgCl2, 1 mM dithiothreitol, and 100 M mant-GTP (Biomol) and a
1 or 2 M concentration (as indicated) of either Cdc42 or RhoA protein,
were prepared and allowed to equilibrate with continuous stirring.
After equilibration, Dbs DH/PH domain was added to 200 nM, and the
rates of GTP loading (kobs) for wild type and mutant Cdc42 proteins
were determined by monitoring the decrease in tryptophan fluorescence
(ex  295 nm, em  335 nm) in response to binding mant-GTP (12–14).
Because of their high intrinsic exchange rate, Cdc42(C18A) and
Cdc42(V33A) were added to equilibrated exchange reactions containing
200 nM Dbs.
To test the inhibition of Dbs-catalyzed exchange by Cdc42(C18A),
400 nM Cdc42(WT) preloaded with mant-GDP was stimulated by 200
nM Dbs DH/PH in the presence of 2 M Cdc42(WT) or Cdc42(C18A),
each bound to GDP. Reaction conditions were similar to those described
above except that 20 M GDP was used in place of 100 M GTP and
exchange was followed by measuring the decrease in fluorescence re-
sulting from mant-GDP release from Cdc42 (ex  360 nm, em  440
nm).
The rates (kobs) of guanine nucleotide exchange were determined by
fitting the data as single exponential decays utilizing GraphPad Prizm
software. Data were normalized to wild type curves to yield the per-
centage of GDP released. All experiments were performed at least in
duplicate.
Surface Plasmon Resonance—Cdc42 binding to Dbs was monitored
using surface plasmon resonance with a BIAcore 2000 instrument at
25 °C. His-tagged Dbs DH/PH domain was immobilized to a nickel
surface on a nitrilotriacetic acid sensor chip (BIAcore) as described by
the manufacturer. Cdc42 solutions (ranging in concentration from 156
nM to 2.5 M) were injected over the stable Dbs surface with or without
50 M EDTA (used to chelate Mg2 and remove nucleotide) at 25 l/min
for 25 s and allowed to dissociate for 60 s in phosphate-buffered saline.
Raw data were normalized to the signal achieved due to binding a
surface lacking Dbs. Normalized sensorgrams were aligned, and the
steady state binding signal from each curve was fit to a single binding
isotherm. The resulting dissociation constants are the mean of several
sets of analyte concentrations.
Molecular Constructs—The pAX142 mammalian expression vector,
pAX142-Cdc42(WT), and pAX-Cdc42(17N) have been described (15, 16).
pAX142-Cdc42(C18A) was generated by PCR-based site-directed mu-
tagenesis and verified by automated sequencing. pAX142-Dbl-HA1 con-
tains a cDNA that encodes a transforming derivative of Dbl fused to an
HA epitope tag (16). GST-PBD contains the Cdc42 binding domains
from the Cdc42/Rac1 effector protein Pak3 (17). The NF-B-luc and
reporter construct utilized in the transcriptional assays have been
described previously (18). pCMVnlac encodes the sequences for the
-galactosidase gene under the control of the cytomegalovirus promoter
(provided by J. Samulski).
Cell Culture, Transfection, and Transient Reporter Gene Assays—
COS-7 cells were maintained in Dulbecco’s modified Eagle’s medium
(high glucose) supplemented with 10% fetal bovine serum. Cells were
transfected by DEAE-dextran (COS-7) as described previously (17).
Cells were allowed to recover for 30 h and subsequently starved in
Dulbecco’s modified Eagle’s medium supplemented with 0.5% serum for
14 h before lysate preparation. Analysis of luciferase expression with
enhanced chemiluminescence reagents and a Monolight 3010 luminom-
eter (Analytical Luminescence, San Diego, CA) was described previ-
ously (19, 20). -Galactosidase activity was determined using Lumi-Gal
substrate (Lumigen, Southfield, MI) according to the manufacturer’s
instructions. All assays were performed in triplicate.
Cdc42 Activation Assays in Vivo—Affinity purification of GTP-Cdc42
was performed as described previously (21). Briefly, the p21 binding
domain of Pak3 was expressed as a GST fusion (GST-PBD) in
BL21(DE3) cells, immobilized to glutathione-coupled Sepharose 4B
beads (Amersham Biosciences) (17), and used to precipitate activated
GTP-bound Cdc42 from COS-7 cell lysates. Cells were washed in cold
phosphate-buffered saline prior to lysis in 50 mM Tris-HCl, pH 7.4, 2
mM MgCl2, 100 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1 g/ml
leupeptin, 1 g/ml pepstatin, 1 g/ml aprotinin, and 1 g/ml phenyl-
methylsulfonyl fluoride. Cell lysates were clarified by centrifugation at
10,000  g for 10 min at 4 °C and normalized for endogenous Cdc42
levels detected by monoclonal antibody (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA). Affinity purifications were carried out at 4 °C for 1 h,
washed three times in an excess of lysis buffer, and then analyzed by
Western blot.
RESULTS
Functional Analysis of the Exchange Mechanism—The struc-
tures of Tiam1 (T-cell lymphoma invasion and metastasis 1),
Dbs, and intersectin in complex with their cognate Rho GT-
Pases (5, 7, 8) suggest that DH domains catalyze exchange by
repositioning the GTPase switch regions to disorganize the
nucleotide binding pocket and directly occlude the Mg2 bind-
ing site. As we have previously described (7), the repositioning
of Cys18, Val33, Ala59, and Glu62 (Cdc42 numbering) within the
complexes appears essential for efficient guanine nucleotide
exchange (Fig. 1). In order to better understand the contribu-
tion of these four residues to the exchange reaction, we have
assessed the mechanistic effects of substitutions at these posi-
tions within Cdc42 using a combination of fluorescence spec-
troscopy to measure guanine nucleotide exchange rates and
surface plasmon resonance to measure affinities of complex
formation.
Cys18 and Val33 apparently undergo a concerted rearrange-
ment within the nucleotide binding pocket upon complex for-
mation, resulting in reorientation of the cysteine side chain
relative to the nucleotide-bound structures of Rho GTPases. In
this new rotamer conformation, Cys18 can no longer hydrogen-
bond to a nucleotide -phosphate (Fig. 1B), and loss of this
hydrogen bond should reduce the affinity for nucleotide and
promote exchange in the absence of GEF. Consequently, and as
expected, substitution of Cys18 to alanine increases the spon-
taneous loading of mant-GTP onto Cdc42 (0.0044/s versus
0.0003/s for Cdc42(WT)), partially mimicking the action of Dbs
(Fig. 2A, Table I). The further stimulation of Cdc42(C18A) by
Dbs (0.0461/s) undoubtedly arises from GEF-induced alter-
ations to portions of the active site outside the phosphate-
binding loop.
Within the GEFGTPase structures (5, 7, 8), the side chains
of residues analogous to Val33 within Cdc42 are moved into the
site normally occupied by Cys18, promoting an alternate rota-
mer conformation of the cysteine residue that can no longer
hydrogen-bond to the -phosphate of guanine nucleotides (Fig.
1B). Therefore, substitution of Val33 to alanine within Cdc42
was designed to decouple structural alterations propagating
from switch 1 to Cys18 within the phosphate binding loop. Since
the rearrangement of Cys18 is predicted to be critically impor-
tant to the GEF-catalyzed exchange reaction, mutation of Val33
was anticipated to hinder Dbs-catalyzed guanine nucleotide
exchange. Experimentally, Cdc42(V33A) bound to Dbs with an
affinity similar to Cdc42(WT) (Fig. 2, G and J, Table I). In
addition, the Dbs-catalyzed rate of mant-GTP loading was only
mildly impaired on Cdc42(V33A) (Fig. 2B, Table I). However,
this observation is complicated by an 5-fold increase in the
intrinsic exchange rate within Cdc42(V33A) versus wild type
(0.0015/s versus 0.0003/s, respectively), reducing the overall
efficiency of Dbs-catalyzed exchange on Cdc42(V33A) (10-fold
versus 72-fold stimulation for wild type) (Table I). These results
are most easily explained by postulating that Val33 is needed
not only to transmit structural alterations within switch 1 to
Cys18 but also to maintain the overall integrity of the nucleo-
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FIG. 2. Kinetic analysis of Cdc42 guanine nucleotide exchange mechanism mutants. Cdc42 mutants containing substitutions C18A (A),
V33A (B), A59G (C), and E62A (D) were tested for the ability to be activated by Dbs. For each mutant, the intrinsic (blue, closed triangles) and
Dbs-catalyzed (red, closed squares) guanine nucleotide exchange rates are shown relative to the equivalent exchange reactions (gray) for
Cdc42(WT) (intrinsic (open triangles) and Dbs-catalyzed (open squares)). Sensorgrams of Cdc42(WT) (E and H), Cdc42(C18A) (F and I), and
Cdc42(V33A) (G and J) showing binding to a Dbs DH/PH domain surface were measured in the presence (E–G) and absence (H–J) of 50 M EDTA
by surface plasmon resonance as described under “Experimental Procedures.” Concentrations of Cdc42 proteins used are 0.156 M (magenta), 0.313
M (purple), 0.625 M (green), 1.25 M (gold), and 2.5 M (red). RU, response units.
FIG. 1. Remodeling of Cdc42 switches.
A, switches (red) of Cdc42 are remodeled
upon binding Dbs. Dbs-bound Cdc42 (5)
(green; every 10th residue numbered) is su-
perimposed on Cdc42 (transparent gray)
bound to GDP (coordinates provided by N.
Nassar) (transparent magenta) and Mg2
(transparent blue). Details of rearrange-
ments for switches 1 (B) and 2 (C) are high-
lighted with arrows, indicating movements
within Cdc42 upon binding Dbs (yellow), and
dashed lines, indicating hydrogen bonds.
Similar conformations of switch 2 are reca-
pitulated in Sos1(Cdc25)Ras (9) (D) and
magnesium-depleted RhoAGDP (30) (E).
The color scheme is consistent with the ear-
lier panels.
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tide binding pocket irrespective of Dbs engagement.
Within conserved region 1 of the Dbs DH domain, the side
chain of Glu639 is clearly critical for stabilizing switch 1 (Fig.
1B) and hydrogen-bonds with the hydroxyl of Tyr32 and the
backbone nitrogens of Thr35 and Val36. The equivalent of
Glu639 is highly conserved among DH domains. Consistent
with the necessity for Dbs to rearrange switch 1 of Cdc42 to
effect exchange, mutation of the conserved glutamate (E639A)
decreases the rates of Dbs-catalyzed exchange upon Cdc42 and
RhoA 29- and 21-fold from wild-type rates, respectively (Fig. 3
and Table II). Residues analogous to Glu639 have been previ-
ously assessed for their role in nucleotide exchange for other
Dbl family members (4, 22), and substitutions at these sites are
consistently detrimental to catalyzed exchange, further indi-
cating a conserved mechanism utilized among Dbl family
proteins.
Ala59 of Cdc42 is repositioned upon complex formation with
Dbs to occlude the Mg2 binding site (Fig. 1C). Glu62 of Cdc42
supports this rearrangement as well as helping to preserve the
integrity of the P-loop through interaction with Lys16. Reposi-
tioning Ala59 (Ala59 in Rac1, Ala61 in RhoA) and Glu62 (Glu62 in
Rac1, Glu64 in RhoA) occurs identically in the structures of
Tiam1Rac1, DbsCdc42, and DbsRhoA, arguing for the impor-
tance of these altered conformations during nucleotide ex-
change of Rho GTPases. Consistent with this structural infor-
mation, both the A59G and E62A mutations in Cdc42 are
extremely deleterious to guanine nucleotide exchange (Fig. 2, C
and D). Both Cdc42(A59G) and Cdc42(E62A) are essentially
unresponsive to Dbs, and despite the fact that Glu62 undergoes
no change in solvent exposure and the Ala59 methyl carbon
loses only 10 Å2 upon complex formation, neither mutant
displays measurable binding to Dbs as indicated by surface
plasmon resonance (Table I). Furthermore, it is interesting to
note that both A59G and E62A decrease the intrinsic rates of
exchange for Cdc42, arguing that disruption of Mg2 binding is
important for spontaneous exchange within the GTPase.
C18A as a Dominant Negative Mutation—When a mutation
in a GTPase decreases affinity for bound nucleotide, the
GTPase may behave as a so-called “dominant negative” in the
presence of its exchange factor, displaying increased affinity
toward the GEF because it is less easily displaced through
nucleotide binding. Accordingly, Cdc42(C18A) binds with in-
creased affinity to Dbs both in the presence and absence of
nucleotide (Fig. 2, F and I; Table I). Consistent with this be-
havior, Cdc42(C18A) effectively inhibits Dbs-catalyzed ex-
change of wild-type Cdc42 in vitro (Fig. 4). Similarly,
Cdc42(C18A) inhibits the ability of Dbl, a close homologue of
Dbs, to elicit transcription by NF-B normally associated with
Cdc42 activation in vivo (Fig. 5). Transcriptional inhibition by
Cdc42(C18A) and the classical dominant-negative
Cdc42(T17N) are roughly equal, indicating that Cdc42(C18A)
is a potent dominant negative of Cdc42 activity.
DISCUSSION
In general, Dbl family proteins catalyze exchange without
directly impinging upon the binding sites for either guanine
nucleotides or the magnesium co-factor. Instead, RhoGEFs ma-
nipulate GTPase residues to promote ejection of GDP and
FIG. 3. Dbs(E639A) exchange of Cdc42 and RhoA. Dbs(E639A) (red lines, open circles) was tested for its ability to catalyze guanine nucleotide
exchange of 1 M Cdc42 (A) or RhoA (B). Also shown are the intrinsic (gray lines, open triangles) and wild-type Dbs-catalyzed (gray lines, open
squares) exchange of Cdc42 and RhoA.
TABLE I
Rate and binding constants for Dbs-catalyzed guanine nucleotide exchange of wild type and mutant Cdc42 proteins
Rates (kobs) of guanine nucleotide exchange for the various Cdc42 proteins were determined by fitting the data from Fig. 2 to a single exponential
decay function. -Fold stimulation is the corresponding ratio of rates for the Dbs-catalyzed versus intrinsic exchange reactions. kobs values are the
mean of at least two experiments with S.D. values. Kd values are estimated from the SPR data in Fig. 2. NB, no binding detected.
2 M Cdc42 Intrinsic rate (kobs)





s1  103 -fold nM nM
WT 0.26  0.01 18.74  1.46 72  5 425 NB
C18A 4.44  0.08 46.07  1.80 10  0 178 457
V33A 1.49  0.04 15.52  0.18 10  0 714 NB
A59G 0.19  0.01 0.79  0.04 4  0 NB NB
E62A 0.18  0.00 0.18  0.02 1  0 NB NB
TABLE II
Rate constants of guanine nucleotide exchange reactions catalyzed by
wild type and mutant Dbs proteins on Cdc42 and RhoA
Rates (kobs) of guanine nucleotide exchange for wild type Cdc42 (left)
or RhoA (right) stimulated by various Dbs proteins were determined by
fitting the data from Fig. 3 as single exponential decays. The -fold
stimulation for each Dbs protein reflects the ratio of kobs measured for




kobs Stimulation kobs Stimulation
s1  103 -fold s1  103 -fold
None 0.28  0.00 0.12  0.00
DH/PH (WT) 19.10  0.01 68.9 4.49  0.06 37.4
E639A 0.67  0.00 2.4 0.21  0.00 1.8
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Mg2. The molecular rearrangements originally seen in Rac1
bound to Tiam1 (7) and recapitulated in the structures of
DbsCdc42 (5), DbsRhoA, and intersectinCdc42 (8) strongly
support the assumption of a conserved exchange mechanism
for all Dbl family proteins.
Specifically, repositioning of switch 1 of Cdc42 moves Phe28
away from the nucleotide base, displaces Thr35 so that it no
longer interacts favorably with the Mg2 ion, and, via Val33,
alters the side chain conformer of Cys18 so that it can no longer
hydrogen-bond with the -phosphate of GDP (Fig. 1B). The
importance of Phe28 was highlighted in a previous study (23),
where substitution of this residue to leucine in Cdc42 results in
a “fast cycling” mutant with spontaneous exchange on par with
Dbl-catalyzed exchange. Less well appreciated is the role of
Cys18 of Cdc42 in binding nucleotides. However, the results
presented here clearly demonstrate a critical role for Cys18 of
Cdc42 in binding nucleotides and participating in a conserved
exchange reaction catalyzed by RhoGEFs. With the exception
of the three Rnd proteins (Rho6/Rnd1, Rho7/Rnd2, and Rho8/
RhoE/Rnd3) that feature an alanine at position 18, all other
Rho family members possess either a cysteine or the isosteric
serine at this position. When Cys18 is substituted to alanine,
Cdc42 loses the ability to bind nucleotide with high affinity,
resulting in rapid exchange. Similarly, alanine at this position
in the Rnd proteins may underlie their relatively high rates of
spontaneous nucleotide exchange (24).
Like the Rnd proteins, Ras possesses an alanine at position
18 that cannot hydrogen-bond to the nucleotide -phosphate.
However, Ras, rather than binding weakly to nucleotides like
the Rnd proteins, possesses other subtle differences in its ac-
tive site and binds nucleotides with higher affinity than the
Rho proteins (25, 26). Nevertheless, Powers et al. (27) have
shown that the A25P mutation in yeast RAS (equivalent to
A18P in human H-Ras) conferred a dominant-interfering phe-
notype. Examination of the nucleotide-bound H-Ras crystal
structure (protein data bank code 121P) reveals that A18P
would disrupt protein-nucleotide interactions primarily by in-
troducing steric conflict with a bound nucleotide, unlike C18A
in Cdc42, which introduces a smaller side chain and directly
abolishes a positive protein-nucleotide interaction.
Furthermore, like Cdc42(C18A), Ras(D119N) has decreased
affinity for nucleotides, resulting in increased affinity of Ras for
its exchange factor, Sos1 (son of sevenless) (23, 28), with asso-
ciated pleiotropic effects in vivo. For instance, at low expression
levels, Ras(D119N) produces a dominant negative phenotype
presumably by sequestering Sos1. However, at expression lev-
els much higher than endogenous GEFs, Ras(D119N) is largely
unbound by GEFs and overly active, since the mutation does
not compromise effector binding and GTP is rapidly loading.
Cdc42(C18A) may behave similarly, and more extensive anal-
yses are necessary to fully understand the consequences of
Cdc42(C18A) expression in vivo.
Finally, a naturally occurring mutation within Ras, A18T,
occurs at the analogous position to Cys18 in Cdc42 and is
associated with excellent prognosis for patients with malignant
melanoma (29). Like Cdc42(C18A), Ras(A18T) also increases
spontaneous nucleotide exchange rates, and we suggest that
Ras(A18T) may inhibit Ras functions and associated tumor
progression by sequestering GEFs.
The importance of stabilizing the conserved conformational
alterations of switch 1 by RhoGEFs is further emphasized by
the role of Glu639 of Dbs (Fig. 1B). This residue makes three
conserved hydrogen bonds to switch 1 of Cdc42 that are crucial
for reconfiguring switch 1 to promote nucleotide ejection. Not
surprisingly, when Glu639 is substituted with alanine (E639A),
Dbs only weakly catalyzes the exchange of nucleotides within
Cdc42 or RhoA.
FIG. 5. The Cdc42(C18A) mutant functions as a dominant in-
hibitor. A, Dbl-HA1 activates Cdc42 in COS-7 cells. COS-7 cells were
transiently transfected with 3 g of pAX142 ( GEF) or pAX142-Dbl-
HA1 ( GEF), along with 3 g of Cdc42(WT). Lysates were collected at
48 h and examined by Western blots for overall expression of Cdc42 and
Dbl-HA1 as indicated as well as activated Cdc42 (GTP-bound) isolated
by affinity purification with GST-PBD. B, Cdc42(C18A) blocks activa-
tion of an NF-B-responsive transcriptional reporter by Dbl-HA1.
COS-7 cells were co-transfected with 3 g of pAX142 (vector), pAX142-
Cdc42(WT), pAX142-Cdc42(17N), or pAX142-Cdc42(C18A), along with
3 g of pAX142-Dbl(HA1), 2.5 g of NF-B-luc, and 500 ng of pCMVnlac
as an internal control for transfection efficiency and/or growth inhibi-
tion. Luciferase and -galactosidase levels were measured and ex-
pressed as -fold activation relative to the level of activation seen with
empty vector control. Luciferase activity was then standardized relative
to -galactosidase activity. Data shown are representative of three
independent experiments performed on triplicate plates. Error bars
indicate S.D. values.
FIG. 4. Cdc42 (C18A) inhibits Dbs exchange of wild type
GTPase. Inhibition of the Dbs-stimulated exchange of mant-GDP-
loaded Cdc42(WT) by Cdc42(C18A). Reactions contained 200 nM Dbs
DH/PH, 400 nM mant-GDP-loaded Cdc42(WT), 20 M GDP, and a 2 M
concentration of either Cdc42(WT) (gray) or Cdc42(C18A) (red). Meas-
ured rates (kobs) for each reaction were 0.0055 s
1 for Cdc42 and 0.0029
s1 for Cdc42(C18A).
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Dbl family proteins stabilize nearly identical conformations
of switch 2 in Rho GTPases, and these conformations are sim-
ilarly recapitulated in the structures of Ras (Fig. 1D) or Ran in
complex with their exchange factors (9, 10) as well as the
structure of RhoA bound to GDP but without magnesium (Fig.
1E) (30). This latter structure is particularly intriguing, since it
may represent a stable intermediate along the reaction coordi-
nate for exchange that is subsequently bound by GEFs (30). In
light of this idea, the failure of Cdc42(E62A) to bind Dbs might
be explained best as a recognition problem; i.e. Cdc42(E62A) is
either never adopting the correct conformation of switch 2
conducive to Dbs-catalyzed exchange, or the sampling of this
conformation is too short lived for productive engagement of
Dbs. In favor of the idea that certain dynamic states of the
switch regions promote binding in native GTPases, Spoerner et
al. (31) have shown that mutation of Thr35 to serine in Ras
dramatically alters the dynamic equilibrium of the effector loop
to favor conformations incompetent for effector binding.
Although the side chain of Ala59 of Cdc42 does make minimal
contact with Dbs, similar to the other RhoGEFGTPase struc-
tures, the primary interaction is through its carbonyl oxygen,
which interacts with a conserved positively charged side chain
within the DH domain (Lys774 in Dbs; Lys1195 in Tiam1;
Arg1384 via a water molecule in intersectin) (Fig. 1C). In theory,
this interaction should be preserved in the A59G mutation.
Nevertheless, Cdc42(A59G) has a greatly reduced affinity for
Dbs under the surface plasmon resonance assay conditions.
This reduction in binding may arise from the introduction of
conformational freedom within switch 2, (similar to that pos-
tulated for Cdc42(E62A)), or the Ala59 side chain may be
instrumental in the transient removal of Mg2 in the absence
of GEF. Since both the A59G and E62A substitutions signif-
icantly reduced the intrinsic rate of exchange of Cdc42, this
latter explanation is an attractive possibility for either
mutant.
Generally, mutations similar to E62A of Cdc42 in other GT-
Pases (Ran(E70A), Ras(E62H)) also severely impair GEF-cat-
alyzed nucleotide exchange (10, 32), suggesting that identical
aspects of GEF-catalyzed exchange are conserved among dif-
ferent GTPase families. However, on a cautionary note, Ala59 of
Ras bound to Sos (9) occupies the same position as Ala59 of
Cdc42 bound to Dbs (Fig. 1, C and D), yet A59G in Ras has no
effect on the rate of GDP release catalyzed by Sos (33). There-
fore, the GEF-catalyzed exchange reactions for Ras and Rho
GTPases do not appear identical despite significant structural
similarities.
Recently, the structure of the bacterial RhoGEF, SopE, has
been determined in complex with nucleotide- and Mg2-free
Cdc42 (11). Interestingly, although SopE is specific for Cdc42
and Rac1 (34), the overall architecture of SopE is unrelated to
DH domains. However, superpositioning of SopE-bound Cdc42
with Dbs-bound Cdc42 reveals that switches 1 and 2 of the
GTPase are in nearly identical conformations when complexed
to either GEF. In addition, key GEF/GTPase interactions with
the switch regions have been preserved, with SopE featuring
Asp124 stabilizing switch 1 (equivalent to Glu639 in Dbs) and
Gln109 (equivalent to Asn810 in Dbs) involved in binding switch
2 (5, 11). Within SopECdc42, Cys18, Val33, Ala59, and Glu62 are
reoriented to nearly identical positions relative to DbsCdc42,
and these residues are presumably similarly involved in nucle-
otide exchange. Overall, these structural similarities suggest
that SopE catalyzes guanine nucleotide exchange of Rho
GTPases similar to Dbl family proteins.
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